DAX24.340 +0,2%Est505.746 -0,1%MSCI World4.343 -0,1%Top 10 Crypto10,94 -5,7%Nas23.593 -0,1%Bitcoin74.586 ±0,0%Euro1,1776 ±0,0%Öl60,64 -2,6%Gold4.533 +1,2%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
NVIDIA 918422 Novo Nordisk A3EU6F Nike 866993 Rheinmetall 703000 DroneShield A2DMAA Allianz 840400 Lufthansa 823212 Deutsche Telekom 555750 Bayer BAY001 Amazon 906866 Tesla A1CX3T BYD A0M4W9 D-Wave Quantum A3DSV9 BASF BASF11 Alphabet A (ex Google) A14Y6F
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX schließt vor Weihnachten etwas höher -- Alphabet kauft Intersect -- Novo Nordisk, D-Wave, Lufthansa, Palantir, TUI, Microsoft, Bitcoin, Gold im Fokus
Top News
Tesla-Aktie: Piper Sandler sieht Meilenstein bei Full Self-Driving in greifbarer Nähe Tesla-Aktie: Piper Sandler sieht Meilenstein bei Full Self-Driving in greifbarer Nähe
Goldpreis, Ölpreis, Silber, Platin & Co. - Das waren die Tops und Flops der Rohstoffe in KW 52 Goldpreis, Ölpreis, Silber, Platin & Co. - Das waren die Tops und Flops der Rohstoffe in KW 52
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

TuHURA Biosciences Aktie

Kaufen
Verkaufen
0,6150 EUR -0,0850 EUR -12,14 %
BMN
0,7952 USD -0,0308 USD -3,73 %
nachbörslich
BTT
TuHURA Biosciences jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.41,03 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA3EWMJ

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS8989201038

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolHURA

TuHURA Biosciences Aktien News

DatumMeistgelesen
PR Newswire/C O R R E C T I O N -- Global X Investments Canada Inc./
PR NewswireGLOBAL X ANNOUNCES DECEMBER 2025 DISTRIBUTIONS FOR ITS SUITE OF ETFs
PR NewswireTuHURA Biosciences Announces its Release of Kintara's Contingent Value Right (CVR) as Kintara's REM-001 Meets Primary Safety Endpoint Achieving Contractual Milestone
Wer­bungTuHURA Biosciences-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR NewswireTuHURA Biosciences Provides Corporate Update Following Recent Financing
PR NewswireTuHURA Biosciences Presents Data Demonstrating the Delta Opioid Receptor (DOR) as a New Target in Overcoming Acquired Resistance to Immune Checkpoint Inhibitors at the 57th ASH Annual Meeting and ...
PR NewswireGLOBAL X ANNOUNCES ESTIMATED 2025 ANNUAL NON-CASH DISTRIBUTION
PR NewswireTuHURA Biosciences, Inc. Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
PR NewswireTuHURA Biosciences Discovery Research on Targeting the Delta Opioid Receptor (DOR) to Reprogram Myeloid-Derived Suppressor Cells (MDSCs) Selected for Oral Presentation at the 67th ASH Annual Meeti...
PR NewswireTuHURA Biosciences, Inc. to Present at the 27th Annual H.C. Wainwright Global Investment Conference
PR NewswireTuHURA Biosciences, Inc. Announces Inclusion in the Russell 3000® and Russell 2000® Indexes
PR NewswireTuHURA Biosciences Completes Acquisition of Kineta
PR NewswireTuHURA Biosciences Initiates Its Phase 3 Accelerated Approval Trial of IFx-2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Advanced or Metastatic Merkel Cell ...
PR NewswireTuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related Proposals
PR NewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HURA and VIGL on Behalf of Shareholders
PR NewswireFDA Removes Partial Clinical Hold on TuHURA Biosciences' Phase 3 Accelerated Approval Trial for IFx-2.0 in Advanced or Metastatic Merkel Cell Carcinoma
PR NewswireTuHURA Biosciences, Inc. Enters into $12.5 Million Equity Financing Transaction and Receives Additional $3.0 Million in Warrant Exercise Proceeds to Advance Its Pipeline of Novel Treatments to Ove...
PR NewswireTuHURA Biosciences Presents IFx-Hu2.0 Trial-in-Progress Poster at the 2025 American Society of Clinical Oncology Annual Meeting
PR NewswireTuHURA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update
PR NewswireTuHURA Biosciences, Inc. to Present at the 3rd Annual H.C. Wainwright BioConnect Conference
PR NewswireTuHURA Biosciences, Inc. Initiates Phase 1b/2a Study of IFx-Hu2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Metastatic Merkel Cell Carcinoma of Unknown Prim...
PR NewswireTuHURA Biosciences and Kineta Present Updated Results from Kineta's Phase I-II Study of KVA12123 and TuHURA's Mechanism of IFx-Hu2.0 Responses After Anti-PD-1 Therapy Failure in Advanced Melanoma ...
PR NewswireTuHURA Biosciences, Inc. Announces Abstracts Accepted for Poster Presentation at the 2025 AACR Annual Meeting
PR NewswireTuHURA Biosciences, Inc. Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management
PR NewswireTuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update
PR Newswire/C O R R E C T I O N -- Global X Investments Canada Inc./
PR NewswireGLOBAL X CONFIRMS 2024 ANNUAL NON-CASH DISTRIBUTIONS
PR NewswireGLOBAL X ANNOUNCES DECEMBER 2024 DISTRIBUTIONS FOR ITS SUITE OF ETFs
PR NewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SHYF, ML, HURA, KANT on Behalf of Shareholders
PR NewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PDCO, ML, HURA, KANT on Behalf of Shareholders
PR NewswireGLOBAL X ANNOUNCES ESTIMATED 2024 ANNUAL NON-CASH DISTRIBUTION

TuHURA Biosciences News

TuHURA Biosciences News: auf dieser Seite finden Sie alle TuHURA Biosciences News und Nachrichten zur TuHURA Biosciences Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch TuHURA Biosciences News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um TuHURA Biosciences News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.